glp·helper
glphelper.com/tirzepatide/texas/killeen
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide
(Mounjaro, Zepbound) in Killeen, TX

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Killeen, TX from the federal NPI registry. Ask each office whether it prescribes Mounjaro or Zepbound.[9]

  • Mounjaro: FDA-approved for type 2 diabetes.
  • Zepbound: FDA-approved for chronic weight management, and obstructive sleep apnea with obesity.
city providers
25
as of today

Same molecule (tirzepatide): Mounjaro in Killeen, Zepbound in Killeen

Other GLP-1 medicines: Ozempic in Killeen, Wegovy in Killeen, Semaglutide in Killeen

§ 02Provider directory: Texas
25 of 25 shown

Find a physician in Killeen.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Tirzepatide by Texas town, physicians per town
§ 03Getting Tirzepatide in Killeen
25 providers · Killeen, TX

How to get Tirzepatide in Killeen.

25 GLP-1 prescribers and 6 local resource types are on record for Killeen, plus 3 nearby towns in the directory.

Physicians in Killeen
25 physicians
25 physicians from the federal NPI registry in Killeen, most listed as Family Medicine (15), Internal Medicine (7) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Harker Heights (24 providers), Copperas Cove (14 providers) and Temple (41 providers).
Around the prescription in Killeen
6 listed nearby
6 dietitians, 6 gyms, 6 fitness clubs, 3 trainers, 6 physiotherapists and 2 places to move are on record near Killeen.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

Bar chart of Tirzepatide dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Tirzepatide comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (brand-specific)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Killeen

Killeen, Texas has a population of 153,095 people. The adult obesity rate in Killeen is an age-adjusted estimate of 46.2%, 10.6 percentage points above the Texas state rate of 35.6%. Diagnosed diabetes reaches 15.1% of adults in Killeen. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 33% of adults in Killeen.

of Killeen adults have obesity
46.2%
diagnosed diabetes
15.1%
no regular physical activity
33%

Age-adjusted estimates for Killeen, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Tirzepatide in Killeen
6 fitness clubs

The prescription is one part. Here is the rest, in Killeen.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Killeen, TX, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Warrior Way Fitness Center
FITNESS
4.5 on Google · 247 reviews
Old Iron side Avenue & BLDG 87030, Red Bud Dr
Website
Planet Fitness
FITNESS
4.6 on Google · 124 reviews
201 E Central Texas Expy
Website
Ironhorse Physical Fitness Center
FITNESS
4.2 on Google · 113 reviews
Old Ironsides Avenue, Tokyo Dr
Website
Elevate Jesus: Women’s Health and Fitness
FITNESS
5.0 on Google · 71 reviews
200 Millers Crossing Ste 104
Website
First National Bank Texas Family Recreation Center
REC CENTER
4.4 on Google · 59 reviews
1700 E Stan Schlueter Loop
Website
Heights Athletic Club - Pickleball, Pool, & Gym
CLUB
4.7 on Google · 50 reviews
701 Sun Meadows Dr
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Elizabeth Buege, RD
RD
Registered dietitian
1901 Veterans Memorial Dr
Call 608-630-1596NPI 1164984761
Nancy Chen, RD
RD
Registered dietitian
2201 Clear Creek Rd
Call 214-502-3887NPI 1609507060
Sara Crews, MS, RDN
RD
Registered dietitian
36065 Santa Fe Ave
Call 254-288-8000NPI 1811469406
Janelle Dietze, RD CSG LD
RD
Registered dietitian
416 N Gray St
Call 254-449-0166NPI 1477703056
Sydney Duquette
RD
Registered dietitian
3401 Rusack Dr
Call 678-654-1598NPI 1023697521
Angela Garcia, RD
RD
Registered dietitian
615 Point Spgs
Call 210-630-2490NPI 1366065245
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Tirzepatide side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Mounjaro's diabetes trials showed lower rates at the same doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 29%
mild
Lowest on Mounjaro 5 mg, highest on Zepbound 10 mg
Diarrhea
12 to 23%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Reported in Mounjaro's diabetes trials
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Tirzepatide costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Tirzepatide monthly cost by how you pay
Zepbound, pharmacy retail$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
Zepbound, LillyDirect self-pay$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Mounjaro, pharmacy retail$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Commercial insurance (weight)Often deniedZepbound is on-label but frequently requires PA
Medicare Part D$0 to $100per monthType 2 diabetes covered. Zepbound KwikPen for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Tirzepatide providers in Killeen

Physicians from the federal NPI registry. Ask each office whether it prescribes Tirzepatide.

Tirzepatide in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Tirzepatide.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Texas

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Tirzepatide is the active ingredient in two Eli Lilly brands: Mounjaro and Zepbound. No generic tirzepatide is FDA-approved in the US. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They share an active ingredient but carry different approved indications, and insurers treat them as separate products.[1]